Income Statement for ANEB

	Anebulo Pharmaceuticals, Inc.
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date			2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31	2023-Sep-30	2023-Jun-30	2023-Mar-31	2022-Dec-31	2022-Sep-30	2022-Jun-30	2022-Mar-31	2021-Dec-31	2021-Sep-30		2021-Mar-31
Fiscal Period			Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023	Q3-FY2023	Q2-FY2023	Q1-FY2023	Q4-FY2022	Q3-FY2022	Q2-FY2022	Q1-FY2021		Q3-FY2020
Total Revenue
Cost Of Revenue
Gross Profit
Gross Margin
Operating Expenses			2,330,884$	1,892,322$	2,588,151$	2,412,124$	1,340,367$	1,664,251$	2,760,459$	2,543,678$	2,494,389$	2,864,041$	3,813,122$	2,612,047$	2,325,484$	1,879,644$	1,071,122$	1,554,924$		552,131$	324,571$	252,346$	173,351$
Operating Income			(2,330,884$)	(1,892,322$)	(2,588,151$)	(2,412,124$)	(1,340,367$)	(1,664,251$)	(2,760,459$)	(2,543,678$)	(2,494,389$)	(2,864,041$)	(3,813,122$)	(2,612,047$)	(2,325,484$)	(1,879,644$)	(1,071,122$)	(1,554,924$)		(552,131$)	(324,571$)
Other Income			486,056$	316,153$	125,121$	211,388$	98,864$	70,405$	74,928$	62,855$	(1,191$)	66,070$	(13,830$)	212$	2,742$	3,153$	(1,869$)	0$		0$	(4,033$)
Interest Income
Interest Expenses			300,000$	100,000$			108,466$	59,696$	31,838$											3,701$			1,286$
Income Before Tax			(2,144,828$)	(1,676,169$)	(2,463,030$)	(2,200,736$)	(1,349,969$)	(1,653,542$)	(2,717,369$)	(2,480,823$)	(2,495,580$)	(2,797,971$)	(3,826,952$)	(2,611,835$)	(2,322,742$)	(1,876,491$)	(1,072,991$)	(1,554,924$)		(555,832$)	(328,604$)	(252,346$)	(173,351$)
Tax Expenses
Income from Continuing Operations			(2,144,828$)	(1,676,169$)	(2,463,030$)	(2,200,736$)	(1,349,969$)	(1,653,542$)	(2,717,369$)	(2,480,823$)	(2,495,580$)	(2,797,971$)	(3,826,952$)	(2,611,835$)	(2,322,742$)	(1,876,491$)	(1,072,991$)	(1,554,924$)		(555,832$)	(328,604$)	(252,346$)	(173,351$)
Income from Discontinued Operations
Consolidated Income			(2,144,828$)	(1,676,169$)	(2,463,030$)	(2,200,736$)	(1,349,969$)	(1,653,542$)	(2,717,369$)	(2,480,823$)	(2,495,580$)	(2,797,971$)	(3,826,952$)	(2,611,835$)	(2,322,742$)	(1,876,491$)	(1,072,991$)	(1,553,395$)		(555,832$)	(328,604$)	(256,379$)	(174,637$)
Net Income			(2,144,828$)	(1,676,169$)	(2,463,030$)	(2,200,736$)	(1,349,969$)	(1,653,542$)	(2,717,369$)	(2,480,823$)	(2,495,580$)	(2,797,971$)	(3,826,952$)	(2,611,835$)	(2,322,742$)	(1,876,491$)	(1,072,991$)	(1,553,395$)		(555,832$)	(328,604$)	(256,379$)	(174,637$)
Profit Margin
Earnings to Minority
Earnings to Common Shareholders			(2,144,828$)	(1,676,169$)	(2,463,030$)	(2,200,736$)	(1,349,969$)	(1,653,542$)	(2,717,369$)	(2,480,823$)	(2,495,580$)	(2,797,971$)	(3,826,952$)	(2,611,835$)	(2,322,742$)	(1,876,491$)	(1,072,991$)	(1,553,395$)		(8,764,225$)	(328,604$)	(256,379$)	(174,637$)
Earnings Per Share, Basic			(0.05$)	(0.04$)	(0.09$)	(0.08$)	(0.05$)	(0.06$)	(0.11$)	(0.10$)	(0.10$)	(0.11$)	(0.15$)	(0.11$)		(0.08$)	(0.05$)	(0.07$)		(0.68$)	(0.03$)	(0.02$)	(0.01$)
Earnings Per Share, Diluted			(0.05$)	(0.04$)	(0.09$)	(0.08$)	(0.05$)	(0.06$)	(0.11$)	(0.10$)	(0.10$)	(0.11$)	(0.15$)	(0.11$)			(0.05$)	(0.07$)		(0.68$)	(0.03$)	(0.02$)	(0.01$)
Average Shares, Basic			40,847,846	41,084,731	27,415,430	25,933,217	25,932,859	25,933,217	25,789,739	25,633,217	25,614,995	25,633,217	25,633,217	23,416,495		23,344,567	23,344,567	23,344,567		12,982,500	12,982,500	12,000,000	12,000,000
Average Shares, Diluted			40,847,846	41,084,731	27,415,430	25,933,217	25,932,859	25,933,217	25,789,739	25,633,217	25,614,995	25,633,217	25,633,217	23,416,495			23,344,567	23,344,567		12,982,500	12,982,500	12,000,000	12,000,000
EBIT			(1,844,828$)	(1,576,169$)	(2,463,030$)	(2,200,736$)	(1,241,503$)	(1,593,846$)	(2,685,531$)	(2,480,823$)	(2,495,580$)	(2,797,971$)	(3,826,952$)	(2,611,835$)	(2,322,742$)	(1,876,491$)	(1,072,991$)	(1,554,924$)		(552,131$)	(328,604$)	(252,346$)	(172,065$)
EBITDA			(1,844,828$)	(1,576,169$)	(2,463,030$)	(2,200,736$)	(1,241,503$)	(1,593,846$)	(2,685,531$)	(2,480,823$)	(2,495,580$)	(2,797,971$)	(3,826,952$)	(2,611,835$)	(2,322,742$)	(1,876,491$)	(1,072,991$)	(1,554,924$)		(552,131$)	(328,604$)	(252,346$)	(172,065$)